traitement des cancers ORL. Cancer Radiother.

traitement des cancers ORL. Cancer Radiother. 2005; 9: 31-6. 13 The department of Veteran Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685-90. 14 Janot F, Rhein B, Koka V. Préservation laryngée par chimiothérapie première. À propos de l’expérience de deux centres du GETTEC dans les cancers de l’endolarynx traités entre 1985 et 1995. Ann Otolaryngol Chir Cervicofac. 2002; 119: 12-20. 15 Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol. 2006; 24: 2629-35. 16 Hitt R, Grau J, Lopez-Pousa A, Berrocal A, García-Giron C, Belon J et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol. 2006; 24(18 s): 283s (abst. 5515). 17 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-8. 18 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006; 64: 983-94. 19 Bernier J, Cooper JS, Pajak TF, Van Glabbeke M, Bouhris J, Forastière A et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27: 843-50. 20 Janot F, De Raucourt D, Castaing M, Bardet E, Dolivet G, Bensadoun R et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups. J Clin Oncol. 2006; 24(18 s): 282s (abst. 5508). 21 Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993; 11: 1873-8. 22 Magné N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O et al. The relationship of epidermal growth factor receptor level to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer. 2001; 37: 2169-77. 23 Harari PM, Huang S. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001; 49: 427-33. 24 Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-78. 25 Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5568-77. 26 Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5578-87. 27 Rivera S, Keryer C, Busson P, Maingon P. Les carcinomas du nasopharynx: de la biologie à la clinique. Cancer Radiother. 2005; 9: 55-68. 28 Julieron M, Temam S. Récidives locorégionales des cancers ORL: place de la chirurgie. Bull Cancer. 2004; 91: 863-9. 29 Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006; 354: 634-6. Poissonnet G, Benezery K, Peyrade F, Bozec A, Bensadoun RJ, Marcy PY et al. to